MB 102

Drug Profile

MB 102

Alternative Names: Anti-CD123 chimeric antigen receptor T cell therapy - Mustang Bio; MB 102 - Mustang Bio; MB102

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator City of Hope National Medical Center
  • Developer Mustang Bio
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 08 Dec 2017 Efficacy and adverse events data from a phase I trial in Acute myeloid leukaemia presented at 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2017)
  • 01 Oct 2017 UMass Medicine Science Park and Mustang bio entered into an agreement to support the clinical development and commercialisation of CAR T therapies
  • 01 Feb 2017 Mustang Bio entered into three amended and restated exclusive patent license agreements for MB 102
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top